Loading...
•
Jun 30, 2023
Royalty Pharma Q2 2023 Earnings Report
Royalty Pharma reported a solid operating cash flow growth and continued business momentum in the second quarter of 2023.
Key Takeaways
Royalty Pharma reported strong financial performance in Q2 2023, with Adjusted Cash Receipts increasing by 4% to $545 million. The company raised its full-year 2023 guidance for Adjusted Cash Receipts to $2.900 to $2.975 billion. Transactions of up to $1.7 billion were announced year-to-date, including $659 million in upfront payments.
Net cash provided by operating activities (GAAP) increased 6% to $608 million.
Adjusted Cash Receipts (non-GAAP) grew 4% to $545 million, driven by strong portfolio performance and new royalties.
Adjusted EBITDA increased 4% to $498 million and Adjusted Cash Flow increased 6% to $512 million.
The company raised its 2023 Adjusted Cash Receipts guidance to $2,900 to $2,975 million.
Revenue by Segment
Forward Guidance
Royalty Pharma anticipates 2023 Adjusted Cash Receipts to be between $2,900 million and $2,975 million, excluding future transactions.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...